Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

POC-HCV

Financiado

Cerrado

Point of care tests to revolutionise the clinical management of patients infecte...

Point of care tests to revolutionise the clinical management of patients infected by Hepatitis C virus Point-of-care (PoC) medical devices have the potential to revolutionise clinical practice. SMEs within our Consortium (Epistem & Biosurfit) have developed genetic and protein PoC devices to deliver on this promise. Results from th... ver más

31/08/2016

INSERM

8M€

Presupuesto del proyecto: 8M€

Líder del proyecto

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHER... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 5 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2016-08-31 No tenemos la información de la convocatoria

0% 75% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

5 Participantes

INSERM

0.00€ | Lider

BIOSURFIT

N.D. | Participante

INSERM TRANSFERT SA

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SCOPE CRISPR Point-of-Care Diagnostics Cerrado

VIRTUALVIALS Virtual vials for enhanced biomolecular analysis 777K€ Cerrado

PARCIVAL Partner Network for a Clinically Validated Multi Analyte Lab... 4M€ Cerrado

PodiTrodi-EU Technology Platform for Point of Care Diagnostics for Tropic... 2M€ Cerrado

BIOCUDET Identify and detect key ocular biomarkers towards personal m... 89K€ Cerrado

HISCREENDIAG Building a Tool to Evaluate and Improve Health Investments i... 473K€ Cerrado

Líder del proyecto

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHER... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 8M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Point-of-care (PoC) medical devices have the potential to revolutionise clinical practice. SMEs within our Consortium (Epistem & Biosurfit) have developed genetic and protein PoC devices to deliver on this promise. Results from these enabling technologies will be integrated using novel bioinformatics tools and algorithms (Qlucore) allowing for bed-side analysis. This integrated genetic-protein approach will exploit recent biomarker discoveries from the FP7 project SPHINX, to improve the management of hepatitis C virus (HCV) infected patients. We will focus on two public health problems: (i) addressing the need to predict, pre-treatment, individuals in resource poor countries (e.g. Egypt) who will benefit from conventional treatment; and (ii) helping to limit treatment costs globally, where new therapies for HCV are anticipated to significantly increase health care expenditures. The predicitve biomarkers are ready for immediate implementation and will greatly improve HCV patient management issues such as decision to treat, selection of therapy, and response-guided monitoring. The predictive power of the SPHINX biomarkers are reliant upon the combination of genetic and protein data. Highlighting the innovative aspect of our proposed work, no clinical algorithms have taken advantage of such a combined genetic / protein biomarker approach for diagnostic tests. To realise this vision, Qlucore will establish patient population-based algorithms that integrate the PoC data on a mobile application, thus facilitating immediate interpretation by physicians. Together, our Consortium will boost prior FP7 discoveries and deliver an integrated platform for predictive and prognostic applications. The associated SMEs will expand their portfolio, but more importantly, our consortium will forge a lasting partnership, formalised by the creation of a new corporation that will have the freedom to market and exploit our collective results.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores